regen labs flexmax bpc-157. BPC-157 in Raleigh, NC BPC-157/TB-500 Blend - RegenMedx |

The primary outcome measurements of the study included change in body weight from baseline to week 26

This triple-blend peptide brings together three distinct molecular pathways studied in connective tissue research and cellular repair models

When looking at the percentage of participants that dropped out of the trial due to adverse effects, 2-6% of patients in the cagrilintide group discontinued treatment early while 7% of the participants receiving liraglutide discontinued treatment early, These findings were in comparison to only 3% of test subjects from the placebo group that discontinued treatment due to adverse events [1]

Cagrilintide applies an analogous half-life-extension logic to a different peptide family, which is part of why the two molecules were later studied together